Kiromic BioPharma, Inc. has reached a settlement with the U.S. Securities and Exchange Commission (SEC) regarding charges related to the non-disclosure of material information about its two cancer-fighting drug candidates. The SEC stated that the company, along with its former CEO and CFO, failed to provide necessary details before, during, and after a public offering that raised $40 million. The settlement was achieved without any financial penalties, acknowledging the company's self-reporting and cooperation with the SEC's investigation. Meanwhile, Grifols is facing scrutiny from institutional investors, particularly Mason Capital Management, which has called for the resignation of board member Tomas Daga, citing conflicts of interest and mismanagement. This pressure follows Brookfield's withdrawal from a proposed acquisition of Grifols, leading JP Morgan to cut its price target for the company by 32%. Additionally, the U.S. has closed its investigation into Gotham City Research, which had previously accused Grifols of deceptive accounting practices.